Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Dr. Lal PathLabs Limited
  6. Summary
    539524   INE600L01024

DR. LAL PATHLABS LIMITED

(539524)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Bombay Stock Exchange
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
3886.4 3794.35 3721.75 3792.8 3704.5 Last
47661 49834 34876 15191 13115 Volume
+6.32% -2.37% -1.91% +1.91% -2.33% Change
Estimated financial data (e)
Sales 2022 20 540 M 273 M 273 M
Net income 2022 3 983 M 53,0 M 53,0 M
Net cash position 2022 11 208 M 149 M 149 M
P/E ratio 2022 77,5x
Yield 2022 0,48%
Sales 2023 22 777 M 303 M 303 M
Net income 2023 4 260 M 56,7 M 56,7 M
Net cash position 2023 13 643 M 181 M 181 M
P/E ratio 2023 70,9x
Yield 2023 0,53%
Capitalization 306 B 4 086 M 4 072 M
EV / Sales 2022 14,4x
EV / Sales 2023 12,8x
Nbr of Employees 3 996
Free-Float 37,9%
More Financials
Company
Dr. Lal PathLabs Limited is an India-based company, which is engaged in providing diagnostic and related healthcare tests and services. It has a network that comprises of a National Reference Laboratory in New Delhi, a Reference Laboratory in Kolkata and approximately 229 other clinical laboratories. The Company is engaged mainly in the business of running laboratories for carrying out pathological investigations of... 
More about the company
Ratings of Dr. Lal PathLabs Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about DR. LAL PATHLABS LIMITED
11/12Dr. Lal Pathlabs Completes Acquisition of Suburban Diagnostics (India)
MT
11/12Dr. Lal PathLabs Limited completed the acquisition of Suburban Diagnostics Private Limi..
CI
10/26Dr. Lal PathLabs' Consolidated Profit Climbs in Fiscal Q2 But Misses Estimates
MT
10/26Dr. Lal PathLabs to Acquire Indian Diagnostics Chain for Over $123 Million
MT
10/26Dr. Lal PathLabs Limited Reports Earnings Results for the Second Quarter and Six Months..
CI
10/26Dr. Lal PathLabs Limited entered into a definitive agreement to acquire Suburban Diagno..
CI
08/03DR LAL PATHLABS : Nomura Adjusts Dr. Lal Pathlabs' Price Target to 2,465 Indian Rupees Fro..
MT
08/02DR LAL PATHLABS : . Lal PhathLabs' Consolidated Profit Soars in Fiscal Q1
MT
07/30Dr. Lal Pathlabs Limited Declares Interim Dividend for the Financial Year 2021-2022, Pa..
CI
07/30Dr. Lal Pathlabs Limited Reports Earnings Results for the First Quarter Ended June 30, ..
CI
07/29Dr. Lal PathLabs Limited Approves Dividend for the Financial Year Ended March 31, 2021
CI
07/06Dr. Lal Pathlabs Limited to Declare Dividend for the Financial Year Ended March 31, 202..
CI
06/18Suburban Diagnostics Reportedly in Sale Talks with Dr. Lal PathLabs, Metropolis, Pharme..
CI
05/24DR LAL PATHLABS : Nomura Adjusts Dr. Lal Pathlabs' Price Target to 2,345 Indian Rupees Fro..
MT
05/24DR LAL PATHLABS' : Consolidated Profit Jumps in Fiscal Q4
MT
More news
News in other languages on DR. LAL PATHLABS LIMITED
11/12Dr. Lal Pathlabs achève l'acquisition de Suburban Diagnostics (Inde)
10/26Le bénéfice consolidé de Dr. Lal PathLabs augmente au deuxième trimestre de l'exercice,..
10/26Dr. Lal PathLabs va acquérir une chaîne de diagnostic indienne pour plus de 123 million..
08/02Le bénéfice consolidé de Dr. Lal PhathLabs s'envole au premier trimestre fiscal
07/30Dr. Lal Pathlabs Limited déclare un dividende intérimaire pour l'exercice 2021-2022, pa..
More news
Analyst Recommendations on DR. LAL PATHLABS LIMITED
More recommendations
Chart DR. LAL PATHLABS LIMITED
Duration : Period :
Dr. Lal PathLabs Limited Technical Analysis Chart | 539524 | INE600L01024 | MarketScreener
Technical analysis trends DR. LAL PATHLABS LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Last Close Price 3 704,50 INR
Average target price 3 294,90 INR
Spread / Average Target -11,1%
EPS Revisions
Managers and Directors
Bharath Uppiliappan Chief Executive Officer
Ved Prakash Goel Chief Financial Officer
Arvind Lal Executive Chairman
Munender Soperna Chief Information Officer
Rajat Kalra Secretary, Compliance Officer & Head-Legal
Sector and Competitors